Common Contracts
9 similar Subscription Agreement contracts by ARCA Biopharma, Inc., Atlas Venture Fund VII L P
EX-10.1 5 dex101.htm FORM OF SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENTSubscription Agreement • May 5th, 2020 • New York
This Subscription Agreement (this “Agreement”) is dated as of April 18, 2011 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • February 1st, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (this “Agreement”) is dated as of January 31, 2013 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • January 23rd, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (the “Agreement”) is dated as of January , 2013 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the Purchaser identified on the signature page hereto (the “Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • December 19th, 2012 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (the “Agreement”) is dated as of December [ ], 2012 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the Purchaser identified on the signature page hereto (the “Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • November 2nd, 2012 • Atlas Venture Fund VII L P • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (the “Agreement”) is dated as of October [ ], 2012 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature page hereto (the “Purchasers”).
SUBSCRIPTION AGREEMENTSubscription Agreement • October 23rd, 2012 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (the “Agreement”) is dated as of October [ ], 2012 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature page hereto (the “Purchasers”).
SUBSCRIPTION AGREEMENTSubscription Agreement • August 3rd, 2012 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (this “Agreement”) is dated as of August 2, 2012 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • December 22nd, 2011 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (the “Agreement”) is dated as of December [ ], 2011 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • April 18th, 2011 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (this “Agreement”) is dated as of April 18, 2011 (the “Effective Date”), between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
